Global Oligonucleotide Drug CDMO Services Market Research Report 2026

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Drug CDMO Services Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 API
1.2.3 Preparation
1.3 Market by Application
1.3.1 Global Oligonucleotide Drug CDMO Services Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 SME Pharmaceutical Company
1.3.3 Large Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Drug CDMO Services Market Perspective (2021–2032)
2.2 Global Oligonucleotide Drug CDMO Services Growth Trends by Region
2.2.1 Global Oligonucleotide Drug CDMO Services Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Oligonucleotide Drug CDMO Services Historic Market Size by Region (2021–2026)
2.2.3 Oligonucleotide Drug CDMO Services Forecasted Market Size by Region (2027–2032)
2.3 Oligonucleotide Drug CDMO Services Market Dynamics
2.3.1 Oligonucleotide Drug CDMO Services Industry Trends
2.3.2 Oligonucleotide Drug CDMO Services Market Drivers
2.3.3 Oligonucleotide Drug CDMO Services Market Challenges
2.3.4 Oligonucleotide Drug CDMO Services Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue
3.1.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue (2021–2026)
3.1.2 Global Oligonucleotide Drug CDMO Services Revenue Market Share by Players (2021–2026)
3.2 Global Top Oligonucleotide Drug CDMO Services Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Oligonucleotide Drug CDMO Services Revenue
3.4 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio
3.4.1 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Drug CDMO Services Revenue in 2025
3.5 Global Key Players of Oligonucleotide Drug CDMO Services Head Offices and Areas Served
3.6 Global Key Players of Oligonucleotide Drug CDMO Services, Products and Applications
3.7 Global Key Players of Oligonucleotide Drug CDMO Services, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Oligonucleotide Drug CDMO Services Breakdown Data by Type
4.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Type (2021–2026)
4.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (2027–2032)
5 Oligonucleotide Drug CDMO Services Breakdown Data by Application
5.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Application (2021–2026)
5.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Oligonucleotide Drug CDMO Services Market Size (2021–2032)
6.2 North America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
6.4 North America Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Drug CDMO Services Market Size (2021–2032)
7.2 Europe Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
7.4 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size (2021–2032)
8.2 Asia-Pacific Oligonucleotide Drug CDMO Services Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2021–2026)
8.4 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Oligonucleotide Drug CDMO Services Market Size (2021–2032)
9.2 Latin America Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
9.4 Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size (2021–2032)
10.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2021–2026)
10.4 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bachem
11.1.1 Bachem Company Details
11.1.2 Bachem Business Overview
11.1.3 Bachem Oligonucleotide Drug CDMO Services Introduction
11.1.4 Bachem Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.1.5 Bachem Recent Development
11.2 WuXi TIDES
11.2.1 WuXi TIDES Company Details
11.2.2 WuXi TIDES Business Overview
11.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Introduction
11.2.4 WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.2.5 WuXi TIDES Recent Development
11.3 Ajinomoto Co
11.3.1 Ajinomoto Co Company Details
11.3.2 Ajinomoto Co Business Overview
11.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Introduction
11.3.4 Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.3.5 Ajinomoto Co Recent Development
11.4 Waters
11.4.1 Waters Company Details
11.4.2 Waters Business Overview
11.4.3 Waters Oligonucleotide Drug CDMO Services Introduction
11.4.4 Waters Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.4.5 Waters Recent Development
11.5 AGC Biologics
11.5.1 AGC Biologics Company Details
11.5.2 AGC Biologics Business Overview
11.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Introduction
11.5.4 AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.5.5 AGC Biologics Recent Development
11.6 Merck KGaA
11.6.1 Merck KGaA Company Details
11.6.2 Merck KGaA Business Overview
11.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Introduction
11.6.4 Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.6.5 Merck KGaA Recent Development
11.7 EUROAPI
11.7.1 EUROAPI Company Details
11.7.2 EUROAPI Business Overview
11.7.3 EUROAPI Oligonucleotide Drug CDMO Services Introduction
11.7.4 EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.7.5 EUROAPI Recent Development
11.8 CordenPharma
11.8.1 CordenPharma Company Details
11.8.2 CordenPharma Business Overview
11.8.3 CordenPharma Oligonucleotide Drug CDMO Services Introduction
11.8.4 CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.8.5 CordenPharma Recent Development
11.9 Cytiva
11.9.1 Cytiva Company Details
11.9.2 Cytiva Business Overview
11.9.3 Cytiva Oligonucleotide Drug CDMO Services Introduction
11.9.4 Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.9.5 Cytiva Recent Development
11.10 TriLink BioTechnologies
11.10.1 TriLink BioTechnologies Company Details
11.10.2 TriLink BioTechnologies Business Overview
11.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Introduction
11.10.4 TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.10.5 TriLink BioTechnologies Recent Development
11.11 Medicilon
11.11.1 Medicilon Company Details
11.11.2 Medicilon Business Overview
11.11.3 Medicilon Oligonucleotide Drug CDMO Services Introduction
11.11.4 Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.11.5 Medicilon Recent Development
11.12 General Biol
11.12.1 General Biol Company Details
11.12.2 General Biol Business Overview
11.12.3 General Biol Oligonucleotide Drug CDMO Services Introduction
11.12.4 General Biol Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.12.5 General Biol Recent Development
11.13 BioSpring
11.13.1 BioSpring Company Details
11.13.2 BioSpring Business Overview
11.13.3 BioSpring Oligonucleotide Drug CDMO Services Introduction
11.13.4 BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.13.5 BioSpring Recent Development
11.14 Bio-Synthesis Inc
11.14.1 Bio-Synthesis Inc Company Details
11.14.2 Bio-Synthesis Inc Business Overview
11.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Introduction
11.14.4 Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.14.5 Bio-Synthesis Inc Recent Development
11.15 Aurisco
11.15.1 Aurisco Company Details
11.15.2 Aurisco Business Overview
11.15.3 Aurisco Oligonucleotide Drug CDMO Services Introduction
11.15.4 Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.15.5 Aurisco Recent Development
11.16 Suzhou Olipharma Co.,Ltd
11.16.1 Suzhou Olipharma Co.,Ltd Company Details
11.16.2 Suzhou Olipharma Co.,Ltd Business Overview
11.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Introduction
11.16.4 Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.16.5 Suzhou Olipharma Co.,Ltd Recent Development
11.17 Porton
11.17.1 Porton Company Details
11.17.2 Porton Business Overview
11.17.3 Porton Oligonucleotide Drug CDMO Services Introduction
11.17.4 Porton Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.17.5 Porton Recent Development
11.18 RIBOPharm
11.18.1 RIBOPharm Company Details
11.18.2 RIBOPharm Business Overview
11.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Introduction
11.18.4 RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (2021–2026)
11.18.5 RIBOPharm Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Oligonucleotide Drug CDMO Services Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Key Players of API
Table 3. Key Players of Preparation
Table 4. Global Oligonucleotide Drug CDMO Services Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 5. Global Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 6. Global Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million), 2021–2026
Table 7. Global Oligonucleotide Drug CDMO Services Market Share by Region (2021–2026)
Table 8. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Region (US$ Million), 2027–2032
Table 9. Global Oligonucleotide Drug CDMO Services Market Share by Region (2027–2032)
Table 10. Oligonucleotide Drug CDMO Services Market Trends
Table 11. Oligonucleotide Drug CDMO Services Market Drivers
Table 12. Oligonucleotide Drug CDMO Services Market Challenges
Table 13. Oligonucleotide Drug CDMO Services Market Restraints
Table 14. Global Oligonucleotide Drug CDMO Services Revenue by Players (US$ Million), 2021–2026
Table 15. Global Oligonucleotide Drug CDMO Services Market Share by Players (2021–2026)
Table 16. Global Top Oligonucleotide Drug CDMO Services Players by Tier (Tier 1, Tier 2, and Tier 3), based on Oligonucleotide Drug CDMO Services Revenue, 2025
Table 17. Ranking of Global Top Oligonucleotide Drug CDMO Services Companies by Revenue (US$ Million) in 2025
Table 18. Global 5 Largest Players Market Share by Oligonucleotide Drug CDMO Services Revenue (CR5 and HHI), 2021–2026
Table 19. Global Key Players of Oligonucleotide Drug CDMO Services, Headquarters and Area Served
Table 20. Global Key Players of Oligonucleotide Drug CDMO Services, Products and Applications
Table 21. Global Key Players of Oligonucleotide Drug CDMO Services, Date of General Availability (GA)
Table 22. Mergers and Acquisitions, Expansion Plans
Table 23. Global Oligonucleotide Drug CDMO Services Market Size by Type (US$ Million), 2021–2026
Table 24. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2021–2026)
Table 25. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (US$ Million), 2027–2032
Table 26. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2027–2032)
Table 27. Global Oligonucleotide Drug CDMO Services Market Size by Application (US$ Million), 2021–2026
Table 28. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2021–2026)
Table 29. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (US$ Million), 2027–2032
Table 30. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2027–2032)
Table 31. North America Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 32. North America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
Table 33. North America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
Table 34. Europe Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 35. Europe Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
Table 36. Europe Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
Table 37. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
Table 38. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million), 2021–2026
Table 39. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Region (US$ Million), 2027–2032
Table 40. Latin America Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 41. Latin America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
Table 42. Latin America Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
Table 43. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
Table 44. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2021–2026
Table 45. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (US$ Million), 2027–2032
Table 46. Bachem Company Details
Table 47. Bachem Business Overview
Table 48. Bachem Oligonucleotide Drug CDMO Services Product
Table 49. Bachem Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 50. Bachem Recent Development
Table 51. WuXi TIDES Company Details
Table 52. WuXi TIDES Business Overview
Table 53. WuXi TIDES Oligonucleotide Drug CDMO Services Product
Table 54. WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 55. WuXi TIDES Recent Development
Table 56. Ajinomoto Co Company Details
Table 57. Ajinomoto Co Business Overview
Table 58. Ajinomoto Co Oligonucleotide Drug CDMO Services Product
Table 59. Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 60. Ajinomoto Co Recent Development
Table 61. Waters Company Details
Table 62. Waters Business Overview
Table 63. Waters Oligonucleotide Drug CDMO Services Product
Table 64. Waters Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 65. Waters Recent Development
Table 66. AGC Biologics Company Details
Table 67. AGC Biologics Business Overview
Table 68. AGC Biologics Oligonucleotide Drug CDMO Services Product
Table 69. AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 70. AGC Biologics Recent Development
Table 71. Merck KGaA Company Details
Table 72. Merck KGaA Business Overview
Table 73. Merck KGaA Oligonucleotide Drug CDMO Services Product
Table 74. Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 75. Merck KGaA Recent Development
Table 76. EUROAPI Company Details
Table 77. EUROAPI Business Overview
Table 78. EUROAPI Oligonucleotide Drug CDMO Services Product
Table 79. EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 80. EUROAPI Recent Development
Table 81. CordenPharma Company Details
Table 82. CordenPharma Business Overview
Table 83. CordenPharma Oligonucleotide Drug CDMO Services Product
Table 84. CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 85. CordenPharma Recent Development
Table 86. Cytiva Company Details
Table 87. Cytiva Business Overview
Table 88. Cytiva Oligonucleotide Drug CDMO Services Product
Table 89. Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 90. Cytiva Recent Development
Table 91. TriLink BioTechnologies Company Details
Table 92. TriLink BioTechnologies Business Overview
Table 93. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product
Table 94. TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 95. TriLink BioTechnologies Recent Development
Table 96. Medicilon Company Details
Table 97. Medicilon Business Overview
Table 98. Medicilon Oligonucleotide Drug CDMO Services Product
Table 99. Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 100. Medicilon Recent Development
Table 101. General Biol Company Details
Table 102. General Biol Business Overview
Table 103. General Biol Oligonucleotide Drug CDMO Services Product
Table 104. General Biol Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 105. General Biol Recent Development
Table 106. BioSpring Company Details
Table 107. BioSpring Business Overview
Table 108. BioSpring Oligonucleotide Drug CDMO Services Product
Table 109. BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 110. BioSpring Recent Development
Table 111. Bio-Synthesis Inc Company Details
Table 112. Bio-Synthesis Inc Business Overview
Table 113. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product
Table 114. Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 115. Bio-Synthesis Inc Recent Development
Table 116. Aurisco Company Details
Table 117. Aurisco Business Overview
Table 118. Aurisco Oligonucleotide Drug CDMO Services Product
Table 119. Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 120. Aurisco Recent Development
Table 121. Suzhou Olipharma Co.,Ltd Company Details
Table 122. Suzhou Olipharma Co.,Ltd Business Overview
Table 123. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product
Table 124. Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 125. Suzhou Olipharma Co.,Ltd Recent Development
Table 126. Porton Company Details
Table 127. Porton Business Overview
Table 128. Porton Oligonucleotide Drug CDMO Services Product
Table 129. Porton Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 130. Porton Recent Development
Table 131. RIBOPharm Company Details
Table 132. RIBOPharm Business Overview
Table 133. RIBOPharm Oligonucleotide Drug CDMO Services Product
Table 134. RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (US$ Million), 2021–2026
Table 135. RIBOPharm Recent Development
Table 136. Research Programs/Design for This Report
Table 137. Key Data Information from Secondary Sources
Table 138. Key Data Information from Primary Sources
Table 139. Authors List of This Report


List of Figures
Figure 1. Oligonucleotide Drug CDMO Services Picture
Figure 2. Global Oligonucleotide Drug CDMO Services Market Size Comparison by Type (US$ Million), 2021–2032
Figure 3. Global Oligonucleotide Drug CDMO Services Market Share by Type: 2025 vs 2032
Figure 4. API Features
Figure 5. Preparation Features
Figure 6. Global Oligonucleotide Drug CDMO Services Market Size by Application (US$ Million), 2021–2032
Figure 7. Global Oligonucleotide Drug CDMO Services Market Share by Application: 2025 vs 2032
Figure 8. SME Pharmaceutical Company Case Studies
Figure 9. Large Pharmaceutical Company Case Studies
Figure 10. Oligonucleotide Drug CDMO Services Report Years Considered
Figure 11. Global Oligonucleotide Drug CDMO Services Market Size (US$ Million), Year-over-Year: 2021–2032
Figure 12. Global Oligonucleotide Drug CDMO Services Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Oligonucleotide Drug CDMO Services Market Share by Region: 2025 vs 2032
Figure 14. Global Oligonucleotide Drug CDMO Services Market Share by Players in 2025
Figure 15. Global Oligonucleotide Drug CDMO Services Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 16. The Top 10 and 5 Players Market Share by Oligonucleotide Drug CDMO Services Revenue in 2025
Figure 17. North America Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 18. North America Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
Figure 19. United States Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 20. Canada Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 21. Europe Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 22. Europe Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
Figure 23. Germany Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 24. France Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 25. U.K. Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 26. Italy Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 27. Russia Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 28. Ireland Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 29. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 30. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Region (2021–2032)
Figure 31. China Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 32. Japan Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 33. South Korea Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 34. Southeast Asia Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 35. India Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 36. Australia & New Zealand Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 37. Latin America Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 38. Latin America Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
Figure 39. Mexico Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 40. Brazil Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 41. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 42. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Country (2021–2032)
Figure 43. Israel Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 44. Saudi Arabia Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 45. UAE Oligonucleotide Drug CDMO Services Market Size YoY Growth (US$ Million), 2021–2032
Figure 46. Bachem Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 47. WuXi TIDES Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 48. Ajinomoto Co Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 49. Waters Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 50. AGC Biologics Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 51. Merck KGaA Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 52. EUROAPI Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 53. CordenPharma Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 54. Cytiva Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 55. TriLink BioTechnologies Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 56. Medicilon Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 57. General Biol Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 58. BioSpring Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 59. Bio-Synthesis Inc Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 60. Aurisco Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 61. Suzhou Olipharma Co.,Ltd Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 62. Porton Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 63. RIBOPharm Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2021–2026)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit